Cochrane · systematic review · CD003546
Management of sexual dysfunction due to antipsychotic drug therapy
Schmidt, HM, Hagen, M, Kriston, L, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
27
current version
GRADE rated
16
No studies
11
Included studies
NR
No studies 11 · 40.7%Ungraded 0 · 0%Very low 12 · 44.4%Low 4 · 14.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL versus PLACEBO for management of sexual dysfunction due to antipsychotic drug therapy
Population: patients with sexual dysfunction due to antipsychotic drug therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sexual function: Subjective assessment (number of erections) ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | no estimate extracted | 1 study · 31 participants | Low |
Sexual function: Objective assessment (Global efficacy questionnaire, improved erections) ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | OR 11.76 [6.54, 21.13] | 1 study · 31 participants | Low |
Leaving the study early ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | RR 0.33 [0.01, 7.62] | 1 study · 32 participants | Very low |
Quality of life Not reported ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: Death Not reported ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: Psychotic symptoms Not reported ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: Extrapyramidal symptoms Not reported ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE versus PLACEBO for management of sexual dysfunction due to antipsychotic drug therapy
Population: patients with sexual dysfunction due to antipsychotic drug therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sexual function: Subjective assessment (Aizenburg's scale) ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO | no estimate extracted | 0 studies · 1 participants | Very low Downgraded: risk of bias |
Leaving the study early ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO | no estimate extracted | 1 study · 10 participants | Very low Downgraded: risk of bias |
Quality of life Not reported ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: Death Not reported ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: Psychopathology (PANSS) ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO | no estimate extracted | 1 study · 10 participants | Very low Downgraded: risk of bias |
Adverse effects: Extrapyramidal symptoms (Simpson‐Angus) ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO | no estimate extracted | 1 study · 10 participants | Very low Downgraded: risk of bias |
SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE versus MAINTENANCE RISPERIDONE for management of sexual dysfunction due to antipsychotic drug therapy
Population: patients with sexual dysfunction due to antipsychotic drug therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sexual function: Subjective assessment (ASEX scale) SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | no estimate extracted | 1 study · 36 participants | Very low Downgraded: risk of bias |
Sexual function: Subjective assessment (prolactin levels, ng/ml) SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias |
Leaving the study early SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | RR 2.2 [0.45, 10.74] | 1 study · 42 participants | Very low Downgraded: risk of bias |
Quality of life Not reported SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | no estimate extracted | NR | No studies |
Adverse effects: Death Not reported SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | no estimate extracted | NR | No studies |
Adverse effects: Psychopathology (PANSS) SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias |
Adverse effects: Extrapyramidal symptoms Not reported SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE | no estimate extracted | NR | No studies |
SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE versus MAINTENANCE RISPERIDONE/FGA for management of sexual dysfunction due to antipsychotic drug therapy
Population: patients with sexual dysfunction due to antipsychotic drug therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sexual function: Subjective assessment (GISF) SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | no estimate extracted | 1 study · 54 participants | Low Downgraded: risk of bias |
Sexual function: Objective assessment (prolactin levels, ng/ml) SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | no estimate extracted | 1 study · 54 participants | Low Downgraded: risk of bias |
Leaving the study early SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | RR 2.25 [0.79, 6.43] | 1 study · 54 participants | Very low Downgraded: risk of bias |
Quality of life Not reported SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | no estimate extracted | NR | No studies |
Adverse effects: Death Not reported SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | no estimate extracted | NR | No studies |
Adverse effects: Psychopathology ‐ various scales SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias |
Adverse effects: Extrapyramidal symptoms ‐ various scales SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias |